Vistagen Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Vistagen Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q2 2024.
  • Vistagen Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$10.7M, a 55.5% decline year-over-year.
  • Vistagen Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$33.2M, a 28.4% increase year-over-year.
  • Vistagen Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.4M, a 50.4% increase from 2022.
  • Vistagen Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$59.2M, a 24% decline from 2021.
  • Vistagen Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$47.8M, a 166% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$33.2M -$10.7M -$3.83M -55.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$29.4M -$9.52M +$2.71M +22.1% Jan 1, 2024 Mar 31, 2024 10-K 2024-06-11
Q4 2023 -$32.1M -$6.35M +$3.41M +34.9% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-13
Q3 2023 -$35.5M -$6.59M +$10.9M +62.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-02-13
Q2 2023 -$46.4M -$6.9M +$12.9M +65.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$59.2M -$12.2M +$4.46M +26.7% Jan 1, 2023 Mar 31, 2023 10-K 2023-06-28
Q4 2022 -$63.7M -$9.76M +$773K +7.34% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-13
Q3 2022 -$64.5M -$17.5M -$4.69M -36.6% Jul 1, 2022 Sep 30, 2022 10-Q 2024-02-13
Q2 2022 -$59.8M -$19.8M -$12M -155% Apr 1, 2022 Jun 30, 2022 10-Q 2024-02-13
Q1 2022 -$47.8M -$16.7M -$10.5M -169% Jan 1, 2022 Mar 31, 2022 10-K 2023-06-28
Q4 2021 -$37.3M -$10.5M -$5.24M -98.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-06-28
Q3 2021 -$32M -$12.8M -$9.5M -288% Jul 1, 2021 Sep 30, 2021 10-K 2023-06-28
Q2 2021 -$22.6M -$7.75M -$4.62M -148% Apr 1, 2021 Jun 30, 2021 10-K 2023-06-28
Q1 2021 -$17.9M -$6.21M -$2.94M -90.1% Jan 1, 2021 Mar 31, 2021 10-K 2021-06-29
Q4 2020 -$15M -$5.3M +$662K +11.1% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-10
Q3 2020 -$15.7M -$3.3M +$2.04M +38.2% Jul 1, 2020 Sep 30, 2020 10-Q 2022-02-10
Q2 2020 -$17.7M -$3.13M +$3.08M +49.6% Apr 1, 2020 Jun 30, 2020 10-Q 2022-02-10
Q1 2020 -$20.8M -$3.27M +$2.46M +42.9% Jan 1, 2020 Mar 31, 2020 10-K 2021-06-29
Q4 2019 -$23.2M -$5.96M +$1.26M +17.4% Oct 1, 2019 Dec 31, 2019 10-K 2021-06-29
Q3 2019 -$24.5M -$5.34M +$2.1M +28.2% Jul 1, 2019 Sep 30, 2019 10-K 2021-06-29
Q2 2019 -$26.6M -$6.21M -$2M -47.4% Apr 1, 2019 Jun 30, 2019 10-K 2021-06-29
Q1 2019 -$24.6M -$5.72M -$1.64M -40.3% Jan 1, 2019 Mar 31, 2019 10-K 2020-06-30
Q4 2018 -$22.9M -$7.22M -$4.21M -140% Oct 1, 2018 Dec 31, 2018 10-K 2020-06-30
Q3 2018 -$18.7M -$7.44M -$2.44M -48.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-06-30
Q2 2018 -$16.3M -$4.21M -$1.95M -86% Apr 1, 2018 Jun 30, 2018 10-K 2020-06-30
Q1 2018 -$14.3M -$4.08M -$1.53M -60% Jan 1, 2018 Mar 31, 2018 10-K 2019-06-25
Q4 2017 -$12.8M -$3.01M -$367K -13.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-06-25
Q3 2017 -$12.4M -$5M -$1.9M -61.1% Jul 1, 2017 Sep 30, 2017 10-K 2019-06-25
Q2 2017 -$10.6M -$2.27M -$297K -15.1% Apr 1, 2017 Jun 30, 2017 10-K 2019-06-25
Q1 2017 -$10.3M -$2.55M +$5.95M +70% Jan 1, 2017 Mar 31, 2017 10-K 2018-06-26
Q4 2016 -$16.2M -$2.64M -$491K -22.9% Oct 1, 2016 Dec 31, 2016 10-K 2018-06-26
Q3 2016 -$15.7M -$3.1M +$3.95M +56% Jul 1, 2016 Sep 30, 2016 10-K 2018-06-26
Q2 2016 -$19.7M -$1.97M +$27.6M +93.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-06-26
Q1 2016 -$47.2M -$8.5M -$2.28M -36.6% Jan 1, 2016 Mar 31, 2016 10-K 2017-06-29
Q4 2015 -$44.9M -$2.15M -$1.06M -97% Oct 1, 2015 Dec 31, 2015 10-K 2017-06-29
Q3 2015 -$43.9M -$7.05M -$5.03M -249% Jul 1, 2015 Sep 30, 2015 10-K 2017-06-29
Q2 2015 -$38.9M -$29.5M -$25M -548% Apr 1, 2015 Jun 30, 2015 10-K 2017-06-29
Q1 2015 -$13.9M -$6.22M -$4.4M -241% Jan 1, 2015 Mar 31, 2015 10-K 2016-06-24
Q4 2014 -$9.49M -$1.09M -$1.22M -932% Oct 1, 2014 Dec 31, 2014 10-K 2016-06-24
Q3 2014 -$8.27M -$2.02M -$562K -38.5% Jul 1, 2014 Sep 30, 2014 10-K 2016-06-24
Q2 2014 -$7.71M -$4.55M -$4.74M -2548% Apr 1, 2014 Jun 30, 2014 10-K 2016-06-24
Q1 2014 -$2.97M -$1.83M +$1.94M +51.6% Jan 1, 2014 Mar 31, 2014 10-K 2015-06-29
Q4 2013 -$4.91M $131K +$5.47M Oct 1, 2013 Dec 31, 2013 10-K 2015-06-29
Q3 2013 -$10.4M -$1.46M +$497K +25.4% Jul 1, 2013 Sep 30, 2013 10-K 2015-06-29
Q2 2013 -$10.9M $186K +$2.01M Apr 1, 2013 Jun 30, 2013 10-K 2015-06-29
Q1 2013 -$12.9M -$3.77M -$727K -23.9% Jan 1, 2013 Mar 31, 2013 10-K 2014-06-25
Q4 2012 -$12.2M -$5.34M -$835K -18.6% Oct 1, 2012 Dec 31, 2012 10-K 2014-06-25
Q3 2012 -$11.3M -$1.96M +$300K +13.3% Jul 1, 2012 Sep 30, 2012 10-K 2014-06-25
Q2 2012 -$11.6M -$1.83M +$585K +24.3% Apr 1, 2012 Jun 30, 2012 10-K 2014-06-25
Q1 2012 -$12.2M -$3.04M +$493K +14% Jan 1, 2012 Mar 31, 2012 10-K 2013-07-18
Q4 2011 -$12.7M -$4.5M -$1.11M -32.6% Oct 1, 2011 Dec 31, 2011 10-K 2013-07-18
Q3 2011 -$11.6M -$2.26M -$684K -43.5% Jul 1, 2011 Sep 30, 2011 10-K 2013-07-18
Q2 2011 -$10.9M -$2.41M -$1.43M -146% Apr 1, 2011 Jun 30, 2011 10-K 2013-07-18
Q1 2011 -$9.48M -$3.54M Jan 1, 2011 Mar 31, 2011 10-K 2013-07-18
Q4 2010 -$3.39M Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-14
Q3 2010 -$1.57M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 -$982K Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.